Korean CML patients monitored on new drug scemblix
NCT ID NCT05943522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 600 Korean adults with chronic myeloid leukemia who are taking Scemblix (asciminib) to see how safe and effective it is in everyday medical practice. Researchers will track side effects and how well the drug controls the disease at 12 and 24 weeks. The goal is to confirm real-world benefits and risks for patients already receiving this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGWŏnju, Gangwon-do, 26426, South Korea
-
Novartis Investigative Site
RECRUITINGAnyang-si, Gyeonggi-do, 14068, South Korea
-
Novartis Investigative Site
RECRUITINGBucheon-si, Gyeonggi-do, 14584, South Korea
-
Novartis Investigative Site
RECRUITINGUijeongbu-si, Gyeonggi-do, 11759, South Korea
-
Novartis Investigative Site
RECRUITINGGyeonggi-do, Korea, 10408, South Korea
-
Novartis Investigative Site
RECRUITINGIncheon, Korea, 405 760, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 02841, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Yangcheon gu, 07985, South Korea
-
Novartis Investigative Site
RECRUITINGSuwon, Yeongtong Gu, 16499, South Korea
-
Novartis Investigative Site
RECRUITINGJeollanam, 519763, South Korea
-
Novartis Investigative Site
RECRUITINGPusan, 614 735, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGTaegu, 41944, South Korea